ORC-13661
Phase 2Small molecule
ORC-13661 is one of 24 small molecule programs targeting Ototoxicity. It is currently in Phase 2.
2
Indications
1
Total Trials
1
Active Trials
23
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
34 competitors in Ototoxicity
#DrugCompanyPhaseTrials
1Cysteine Hydrochloride
NovartisPhase 3
Qualaquin
BBiomed Industries, Inc.
Approved
Artemether/lumefantrine
Merck & Co.Approved
Atovaquone/proguanil
PfizerApproved
Crestor
AstraZenecaPhase 2
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 2
N-Acetyl Cyteien
SStanford University
Phase 2
Ginkgo Biloba Extract
NNational Center for Complementary and Integrative Health (NCCIH)
Phase 2
Avlosulfon
AAlmirall, S.A.
Phase 1
Acetyl Cysteine
TTanta University
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ORC-13661. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- KKevin Winthrop